288 results match your criteria Reviews in Gastroenterological Disorders[Journal]


Prevalence and risk factors of fecal incontinence in community-dwelling men.

Rev Gastroenterol Disord 2009 ;9(4):E97-110

Minnesota Evidence-based Practice Center, Minneapolis, USA.

Fecal incontinence (FI) in community-dwelling men affects quality of life and increases the risk of institutionalization. Observational studies and randomized, controlled trials (RCTs) on epidemiology and prevention of FI published in English from 1990 to November 2007 were identified in several databases to abstract rates and adjusted odds ratios (ORs) of incontinence and to synthesize evidence with random effects models. Twenty-one observational studies and 4 RCTs were eligible for analysis. Read More

View Article

Download full-text PDF

Source
April 2010
5 Reads

Diarrhea - novel transdermal patch vaccine to prevent travelers' diarrhea.

Rev Gastroenterol Disord 2009 ;9(4):E119-20

Department of Medicine, Eastern Virginia Medical School, Norfolk, USA.

View Article

Download full-text PDF

Source
April 2010
7 Reads

Peptic ulcer bleeding following therapeutic endoscopy: a new indication for intravenous esomeprazole.

Authors:
Danial E Baker

Rev Gastroenterol Disord 2009 ;9(4):E111-8

Drug Information Center, Department of Pharmacotherapy, Washington State University, Spokane, USA.

Intravenous (IV) administration of the esomeprazole is a faster way to achieve gastric acid suppression than oral administration of the same agent. Peak suppression following IV administration occurs within hours compared with several days following oral administration. Thus, the IV administration route offers a faster onset of gastric suppression, achievement of intragastric pH closer to target levels, and better bioavailability. Read More

View Article

Download full-text PDF

Source
April 2010
3 Reads

Diarrhea--cryptosporidial diarrhea in patients with AIDS: impressive results with Rifaximin.

Rev Gastroenterol Disord 2009 ;9(3):E94-5

Division of Infectious Diseases, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA, USA.

View Article

Download full-text PDF

Source
March 2010
4 Reads

Methylnaltrexone bromide: new drug for the treatment of opioid-induced bowel dysfunction.

Authors:
Danial E Baker

Rev Gastroenterol Disord 2009 ;9(3):E84-93

Drug Information Center, Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, WA, USA.

Constipation is a common problem associated with opiates and opioid compounds used for the treatment of pain and other medical conditions, and can influence patient quality of life. Methylnaltrexone appears effective in the therapy of opioid-induced constipation and will be useful for patients failing to respond to traditional laxative regimens. Read More

View Article

Download full-text PDF

Source
March 2010
7 Reads

Antimicrobial resistance and eradication strategies for Helicobacter pylori.

Authors:
Nimish Vakil

Rev Gastroenterol Disord 2009 ;9(3):E78-83

University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

Antimicrobial resistance is a major cause for failed Helicobacter pylori eradication. This article discusses the prevalence and mechanisms of resistance in H pylori and presents a strategy for eradication in patients harboring resistant strains. Read More

View Article

Download full-text PDF

Source
March 2010
7 Reads

The future of inflammatory bowel disease care.

Rev Gastroenterol Disord 2009 ;9(3):E69-77

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN,USA.

This article summarizes the David Sun Lecture at the American College of Gastroenterology in Orlando, Florida, that was delivered on October 4, 2008. The lecture, entitled "The Future Direction of IBD Care," reviewed the future use of current drugs (such as 5-aminosalicylate, steroids, immunosuppressive medications, and biologic agents) and upcoming drugs in the treatment of IBD. Read More

View Article

Download full-text PDF

Source
March 2010
9 Reads

Diarrhea. Enterotoxigenic Bacteroides fragilis: newly recognized cause of inflammatory diarrhea.

Rev Gastroenterol Disord 2009 ;9(2):E65-6

Division of Infectious Diseases, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA, USA.

View Article

Download full-text PDF

Source
November 2009
7 Reads

Helicobacter pylori. Can Helicobacter pylori infection prevent allergic asthma?

Authors:
Nimish Vakil

Rev Gastroenterol Disord 2009 ;9(2):E66-7

University of Wisconsin School of Medicine and Public Health, Madison WI, USA.

View Article

Download full-text PDF

Source
November 2009
4 Reads

Diarrhea. Best option for traveler's diarrhea: loperamide plus an antibiotic?

Rev Gastroenterol Disord 2009 ;9(2):E63-4

Division of Infectious Diseases, Department of Medicine, Eastern Virginia Medical School, Norfolk, VA, USA.

View Article

Download full-text PDF

Source
November 2009
3 Reads

Reflux monitoring.

Rev Gastroenterol Disord 2009 ;9(2):E54-62

Albert Einstein Medical Center, Philadelphia, PA, USA.

There are several available diagnostic options to evaluate patients with suspected gastroesophageal reflux, whether acid, weakly acid, or nonacid. The appropriate application of these technologies is the subject of much discussion among experts. Thoughtful use of reflux monitoring is of great benefit in the evaluation of patients with endoscopy-negative disease reflux symptoms that are resistant, recurrent, or refractory to standard or double-dose antisecretory therapy; patients with distinct, atypical symptoms such as cough, laryngitis, chest pain, globus, or regurgitation in whom heartburn is infrequent or absent; patients who are seeking surgical or endoscopic corrective procedures to treat their symptoms; and those with recurrence of symptoms after undergoing surgical procedures. Read More

View Article

Download full-text PDF

Source
November 2009
9 Reads

Functional (non-ulcer) dyspepsia and gastroparesis--differentiating these conditions and practical management approaches.

Rev Gastroenterol Disord 2009 ;9(2):E48-53

Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA.

Because of the limited therapeutic options, management of patients with functional dyspepsia can be remarkably difficult. This review considers the current state of the art for patients who present with unexplained dyspepsia, and outlines a practical management approach for clinicians. Read More

View Article

Download full-text PDF

Source
November 2009
4 Reads

Screening and diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis.

Rev Gastroenterol Disord 2009 ;9(2):E41-7

Division of Gastroenterology & Hepatology, Weill Cornell Medical Center, New York, NY, USA.

Primary sclerosing cholangitis (PSC) is an idiopathic cholestatic liver disease which predisposes to the development of cholangiocarcinoma (CCA). Detection of CCA in PSC patients remains difficult and CCA is often found incidentally at autopsy or in explanted livers post-transplantation for PSC. In addition, considerable overlap exists between the symptoms of CCA and those of benign dominant strictures encountered commonly in PSC. Read More

View Article

Download full-text PDF

Source
November 2009
9 Reads

Infectious disease. Early loss of immune cells and progressive immunodeficiency in HIV infection: it's all about the gut.

Rev Gastroenterol Disord 2009 ;9(1):35-9

Division of Infectious Diseases, Department of Medicine, Eastern Virginia Medical School, Norfolk, Virginia, USA.

View Article

Download full-text PDF

Source
June 2009
5 Reads

Definitive therapy for internal hemorrhoids--new opportunities and options.

Rev Gastroenterol Disord 2009 ;9(1):16-26

David Geffen School of Medicine at UCLA, Greater Los Angeles VA Healthcare Center, Center for Ulcer Research and Education (CURE): Digestive Diseases Research Center, Los Angeles, California, USA.

Hemorrhoids are common in Western societies. Appropriate assessment and treatment of symptomatic hemorrhoids can substantially reduce morbidity and improve patient well-being. In this article, the clinical presentation, differential diagnoses, and current treatment options, including the CRH-O'Regan banding device, an emerging technology for the anoscopic treatment of symptomatic internal hemorrhoids, are reviewed. Read More

View Article

Download full-text PDF

Source
June 2009
16 Reads

Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome.

Rev Gastroenterol Disord 2009 ;9(1):7-15

Division of Gastroenterology, Department of Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Irritable bowel syndrome (IBS) is a common disorder with widespread prevalence. Due to its heterogeneous pathogenesis, efficacious treatments are lacking. The few medications that are effective for treating global IBS symptoms have either been withdrawn or restricted due to detrimental side effects; thus, safe and effective alternatives are urgently needed. Read More

View Article

Download full-text PDF

Source
June 2009
8 Reads

Third Eye Retroscope: rationale, efficacy, challenges.

Authors:
Douglas K Rex

Rev Gastroenterol Disord 2009 ;9(1):1-6

Department of Medicine, Division of Gastroenterology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

The most effective colonoscopy misses polyps, and both barium enema and computed tomography colonography studies have identified hidden areas on the proximal sides of folds, flexures, and valves where colonoscopy can miss even substantially sized lesions. This article reviews the rationale, efficacy, and clinical challenges associated with one of the most promising devices for improvement of mucosal exposure during colonoscopy, the Third Eye Retroscope (Avantis Medical, Sunnyvale, CA). Read More

View Article

Download full-text PDF

Source
June 2009
11 Reads

Diagnosis and management of esophageal disease.

Authors:
Philip O Katz

Rev Gastroenterol Disord 2008 ;8(4):272-4

Division of Gastroenterology, Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
March 2009
7 Reads

Mucosal healing in inflammatory bowel disease.

Rev Gastroenterol Disord 2008 ;8(4):271-2

Mayo Clinic, Rochester, Minnesota, USA.

View Article

Download full-text PDF

Source
March 2009
7 Reads

Infectious disease. Vancomycin should be the drug of choice for severe Clostridium difficile-associated diarrhea.

Rev Gastroenterol Disord 2008 ;8(4):270-1

Division of Infectious Diseases, Department of Medicine, Eastern Virginia Medical School, Norfolk, Virginia, USA.

View Article

Download full-text PDF

Source
March 2009
5 Reads

Certolizumab pegol: a polyethylene glycolated Fab' fragment of humanized anti-tumor necrosis factor alpha monoclonal antibody for the treatment of Crohn's disease.

Authors:
Danial E Baker

Rev Gastroenterol Disord 2008 ;8(4):240-53

Drug Information Center, College of Pharmacy, Washington State University Spokane, Spokane, Washington, USA.

Certolizumab pegol offers an alternative to the other biologic response modifiers for the treatment of Crohn's disease. Results from phase II dose-ranging studies were mixed because a number of the studies had high placebo response rates and a large number of patients with low C-reactive protein (CRP) levels. Phase III clinical trials have demonstrated induction of clinical responses and maintenance of remission for patients independent of whether baseline CRP levels were normal or elevated. Read More

View Article

Download full-text PDF

Source
March 2009
9 Reads

Gastroesophageal reflux disease and obesity.

Rev Gastroenterol Disord 2008 ;8(4):233-9

Division of Gastroenterology, Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA.

Although the balance of epidemiologic data supports a relationship between obesity and gastroesophageal reflux disease (GERD), it is difficult to establish true cause and effect. However, results of several studies show that the frequency and severity of GERD symptoms and complications may be higher in obese patients, including an increase in the presence of hiatal hernia. Additionally, findings of a recent meta-analysis demonstrate a statistically significant increase in the risk for GERD symptoms, erosive esophagitis, and esophageal adenocarcinoma in obese patients. Read More

View Article

Download full-text PDF

Source
March 2009
7 Reads

Advances in colonoscope technique and technology.

Rev Gastroenterol Disord 2008 ;8(4):223-32

Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.

To date, no alternative platform for colonoscopy seems prepared to substantially supplant the traditional colonoscopy platform. The Invendoscope and capsule colonoscopy are the most promising of the alternative platforms. With regard to colonoscope insertion, water immersion is quite noteworthy but requires additional study in broader populations. Read More

View Article

Download full-text PDF

Source
March 2009
9 Reads

Infectious disease. Probiotics for the prevention of diarrhea associated with antibiotics.

Rev Gastroenterol Disord 2008 ;8(3):221-2

Division of Infectious Diseases, Department of Medicine, Eastern Virginia Medical School, Norfolk, Virginia, USA.

View Article

Download full-text PDF

Source
November 2008
273 Reads

Liver disease. The influence of SOCS3 expression on the treatment response of HCV-related chronic hepatitis patients.

Rev Gastroenterol Disord 2008 ;8(3):218-21

Internal Medicine Department at Lutheran Medical Center, Brooklyn, NY, USA.

View Article

Download full-text PDF

Source
November 2008
5 Reads

New developments in the treatment of Helicobacter pylori: is sequential therapy the answer?

Authors:
Nimish Vakil

Rev Gastroenterol Disord 2008 ;8(3):217-8

University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

View Article

Download full-text PDF

Source
November 2008
7 Reads

Key opinion leader interview. Fospropofol disodium: new perspectives on endoscopic procedures.

Authors:
Lawrence B Cohen

Rev Gastroenterol Disord 2008 ;8(3):213-6

Division of Gastroenterology, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA.

View Article

Download full-text PDF

Source
November 2008
6 Reads

Advances in endoscopic imaging: narrow band imaging.

Rev Gastroenterol Disord 2008 ;8(3):186-93

Veterans Affairs Medical Center and University of Kansas School of Medicine, Kansas City, Missouri, USA.

Technological advances in endoscopic imaging are constantly being evaluated in clinical research, and encouraging results are being seen. Studies on practical applications of these new technologies are ongoing in conditions as diverse as gastroesophageal reflux disease, Barrett's esophagus, colonic polyps, and dysplasia in ulcerative colitis. This review discusses the recent advances in endoscopic imaging that appear to be on the verge of widespread and routine usage. Read More

View Article

Download full-text PDF

Source
November 2008
9 Reads

Chronic unexplained diarrhea: what to do when the initial workup is negative?

Rev Gastroenterol Disord 2008 ;8(3):178-85

Department of Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic Jacksonville, Jacksonville, Florida, USA.

Diagnosing the patient with chronic diarrhea can still be a major challenge despite modern testing. It is useful initially to consider what may be the likely underlying pathophysiologic explanation for diarrhea from the history (osmotic, secretory, inflammatory, or motility related) and let this information drive the management algorithm. However, gastroenterologists frequently ask how far the workup should go and when a confident diagnosis of functional diarrhea can be made. Read More

View Article

Download full-text PDF

Source
November 2008
4 Reads

Small bowel enteroscopy.

Rev Gastroenterol Disord 2008 ;8(3):169-77

Section of Therapeutic Endoscopy, Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio, USA.

For the examination of the small bowel in patients with suspected small bowel bleeding, endoscopic tools to perform deep enteroscopy have become essential. Double balloon enteroscopy has gained worldwide acceptance as an endoscopic technique that can be used safely and effectively to provide complete examination of the small bowel, offer therapeutic intervention, and favorably affect clinical outcomes. Single balloon enteroscopy seems to have utility similar to that of the double balloon system. Read More

View Article

Download full-text PDF

Source
November 2008
21 Reads

Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease.

Rev Gastroenterol Disord 2008 ;8(3):159-68

Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.

With the introduction of biologic therapies for inflammatory bowel disease, significant questions have arisen regarding their best optimization. Although initial recommendations were to combine immunosuppressives with biologics to reduce immunogenicity, trials with 3 different anti-tumor necrosis factor agents (infliximab, adalimumab, and certolizumab) and a humanized monoclonal antibody that targets alpha-4 integrins (natalizumab) have failed to demonstrate the clinical superiority of combination therapy when high-dose induction and scheduled maintenance therapy was prescribed for up to 1 year. However, immunosuppressive agents should be considered with episodic biologic therapy to decrease immunogenicity and secondary loss of response. Read More

View Article

Download full-text PDF

Source
November 2008
3 Reads

Use of a rifaximin "chaser" in the treatment of recurrent Clostridium difficile-associated diarrhea.

Rev Gastroenterol Disord 2008 ;8(2):157-8

Division of Infectious Diseases, Department of Medicine, Eastern Virginia Medical School, Norfolk, Virginia, USA.

View Article

Download full-text PDF

Source
October 2008
6 Reads

A new one-two punch against traveller's diarrhea: azithromycin plus loperamide.

Rev Gastroenterol Disord 2008 ;8(2):155-7

Division of Infectious Diseases, Department of Medicine, Eastern Virginia Medical School, Norfolk, Virginia, USA.

View Article

Download full-text PDF

Source
October 2008
25 Reads

New pharmacological agents for the treatment of gastroesophageal reflux disease.

Authors:
Nimish Vakil

Rev Gastroenterol Disord 2008 ;8(2):117-22

University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Proton pump inhibitors (PPIs) are currently the most effective and most widely used agents for gastroesophageal reflux disease (GERD). Despite the efficacy of these agents in healing and symptom relief, a substantial proportion of patients require twice-daily therapy with PPIs, and break-through symptoms cause others to use over-the-counter antacids and histamine 2-receptor antagonists to supplement their PPI therapy. Major strategies that are being pursued include the development of agents that have a faster onset of action for on-demand therapy; have better control of acid secretion, resulting in improved healing in advanced grades of esophagitis and better symptom control; and agents that decrease transient lower esophageal sphincter relaxations (TLESRs), thereby reducing distal acid exposure and weakly acidic refluxate. Read More

View Article

Download full-text PDF

Source
October 2008
4 Reads

Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies.

Rev Gastroenterol Disord 2008 ;8(2):109-16

Inflammatory Bowel Disease Clinic, Gastroenterology Training Program, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.

The current guidelines for the management of Crohn's disease (CD) suggest a stepwise approach to treatment according to the severity of clinical presentation. The use of tumor necrosis factor (TNF) antagonists are currently reserved for patients who do not respond to conventional nonbiological therapies such as corticosteroids and immunosuppressants. However, as TNF-alpha antagonists have the potential to produce mucosal healing in CD, earlier more aggressive treatment with biologics has been advocated. Read More

View Article

Download full-text PDF

Source
October 2008
11 Reads

Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies.

Rev Gastroenterol Disord 2008 ;8(2):98-108

Division of Gastroenterology, Eastern Virginia Medical School, Norfolk, Virginia, USA.

The consequences of nocturnal gastroesophageal reflux disease (GERD) may be greater than daytime GERD in terms of clinical complications such as increased risk of esophageal lesions and respiratory conditions, as well as issues of health-related quality of life, sleep, work productivity, and economics. Proton pump inhibitors (PPIs) are the most effective therapy for patients with GERD; however, treatment success is greater in the improvement of daytime symptoms and acid control. Acid suppression of most PPIs, which are administered once daily before breakfast, wanes during the nighttime hours. Read More

View Article

Download full-text PDF

Source
October 2008
11 Reads

Enteral and colonic self-expanding metallic stents.

Rev Gastroenterol Disord 2008 ;8(2):83-97

Department of Medicine, University of Minnesota, Hennepin County Medical Center, Minneapolis, Minnesota, USA.

Self-expanding metal stents (SEMS) have changed the management of malignant gastrointestinal obstruction. In malignant gastroduodenal obstruction for which curative surgical resection is not possible, endoscopic placement of SEMS is an ideal option. Endoscopic placement of SEMS has a high rate of technical and clinical success and a low rate of complications. Read More

View Article

Download full-text PDF

Source
October 2008
14 Reads

Helicobacter pylori treatment: is sequential or quadruple therapy the answer?

Authors:
Nimish Vakil

Rev Gastroenterol Disord 2008 ;8(2):77-82

University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Clarithromycin resistance is a growing problem in many countries. Eradication rates for Helicobacter pylori have declined to unacceptable levels in recent years, in large measure because of clarithromycin resistance. Two treatment strategies (quadruple therapy and sequential therapy) are emerging as alternatives to triple therapy for the initial treatment of patients infected with H. Read More

View Article

Download full-text PDF

Source
October 2008
8 Reads

Infectious disease. The nose knows.

Rev Gastroenterol Disord 2008 ;8(1):74-5

Division of Infectious Diseases, Department of Medicine, Eastern Virginia Medical School, Norfolk, Virginia, USA.

View Article

Download full-text PDF

Source
July 2008
15 Reads

Esophageal disease. Intragastric pH control and healing of erosive esophagitis.

Authors:
Philip O Katz

Rev Gastroenterol Disord 2008 ;8(1):72-3

Division of Gastroenterology and Nutrition, Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
July 2008
14 Reads

Infectious disease. Endocarditis prophylaxis: new guideline, much less antibiotic prophylaxis.

Rev Gastroenterol Disord 2008 ;8(1):73-4

Division of Infectious Diseases, Department of Medicine, Eastern Virginia Medical School, Norfolk, Virginia, USA.

View Article

Download full-text PDF

Source
July 2008
9 Reads

Esophageal disease. Screening and surveillance for Barrett's esophagus: esophageal capsule versus conventional endoscopy.

Authors:
Philip O Katz

Rev Gastroenterol Disord 2008 ;8(1):71-3

Division of Gastroenterology and Nutrition, Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
July 2008
14 Reads

Pylera plus omeprazole: quadruple treatment for Helicobacter pylori.

Authors:
Danial E Baker

Rev Gastroenterol Disord 2008 ;8(1):33-41

College of Pharmacy, Washington State University, Spokane, Washington, USA.

In 2007, the American College of Gastroenterology published updated treatment guidelines for the management of Helicobacter pylori infection, the leading cause of peptic ulcers. The recommended effective therapies are a triple drug regimen for 14 days or a quadruple bismuth therapy for 10 to 14 days, which includes a combination of a proton pump inhibitor such as omeprazole, bismuth, metronidazole, and tetracycline. These drug regimens all require strict adherence and several pills daily, but recent formulations have lessened the pill burden, which can improve patient compliance and outcomes. Read More

View Article

Download full-text PDF

Source
July 2008
5 Reads

Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis.

Rev Gastroenterol Disord 2008 ;8(1):21-30; quiz 31-2

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Recent evidence suggests that there is a link between increased colonic inflammation and risk of colorectal cancer, stressing the importance of preventing relapse. The risk of relapse is associated with several factors, of which the foremost is patient nonadherence to prescribed medical therapy. Nonadherence may be affected by such factors as complicated dosing regimens, forgetfulness, male sex, and treatment delivery methods. Read More

View Article

Download full-text PDF

Source
July 2008
3 Reads

The role of loperamide in gastrointestinal disorders.

Rev Gastroenterol Disord 2008 ;8(1):15-20

Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, Illinois, USA.

Loperamide is an effective therapy for a variety of diarrheal syndromes, including acute, nonspecific (infectious) diarrhea; traveler's diarrhea; and chemotherapy-related and protease inhibitor?associated diarrhea. Loperamide is effective for the "gut-directed" symptom of diarrhea in patients with painless diarrhea or diarrhea-predominant irritable bowel syndrome. Loperamide and diphenoxylate are commonly used to treat diarrhea in numerous settings of inflammatory bowel disease. Read More

View Article

Download full-text PDF

Source
July 2008
13 Reads

New frontiers in small-bowel imaging: the expanding technology of capsule endoscopy and its impact in clinical gastroenterology.

Rev Gastroenterol Disord 2008 ;8(1):1-14

Division of Gastroenterology and Hepatology, and Transplantation Medicine, Mayo Clinic, Scottsdale, Arizona, USA.

Capsule endoscopy (CE) is now recognized as a significant technologic advancement in gastrointestinal endoscopy that provides noninvasive, high-resolution imaging of the small bowel and esophagus. There is also growing evidence that it may be useful in the colon. Since the introduction of CE to clinical practice, its diagnostic utility has become well established for evaluation of patients with obscure gastrointestinal bleeding. Read More

View Article

Download full-text PDF

Source
July 2008
5 Reads

Treatment of diarrhea in patients with inflammatory bowel disease: concepts and cautions.

Rev Gastroenterol Disord 2007 ;7 Suppl 3:S3-10

Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, Illinois, USA.

Diarrhea continues to be a prevalent symptom in patients with inflammatory bowel disease (IBD), requiring a wide differential diagnosis to define the pathophysiologic mechanisms in individual patients. It is essential that physicians properly evaluate complaints of diarrhea by assessing both patient symptoms and potential physiologic impacts on fluid and electrolyte status. Underlying mechanisms of diarrhea with IBD are the location, extent, and severity of inflammation; malabsorption; altered motility; and iatrogenic causes such as medications, diet, and antibiotic-associated colitis (eg, Clostridium difficile). Read More

View Article

Download full-text PDF

Source
February 2008
3 Reads

Management of diarrhea in clinical practice: strategies for primary care physicians.

Rev Gastroenterol Disord 2007 ;7 Suppl 3:S27-38

Digestive Health Associates of Texas, Baylor University Medical Center, Dallas, Texas, USA.

The evaluation and management of diarrhea can be a challenging problem for primary care physicians. The differential diagnosis is large and the multiplicity of diagnostic tests makes the evaluation complex. A strategy of taking a thorough history and performing simple objective tests can make the diagnostic process easier. Read More

View Article

Download full-text PDF

Source
February 2008
5 Reads

A practical approach to treating patients with chronic diarrhea.

Authors:
Joseph H Sellin

Rev Gastroenterol Disord 2007 ;7 Suppl 3:S19-26

Division of Gastroenterology, University of Texas Medical Branch, Galveston, Texas, USA.

Although diarrhea is a common complaint, its evaluation and treatment can be challenging. Appropriately defining and classifying diarrhea provide the framework for approaching diagnostic and therapeutic options. Diarrhea can be defined based on frequency, consistency, and/or weight, and classified as acute or chronic with specific clinical characteristics and stool appearance. Read More

View Article

Download full-text PDF

Source
February 2008
6 Reads

Loperamide: a pharmacological review.

Authors:
Daniel E Baker

Rev Gastroenterol Disord 2007 ;7 Suppl 3:S11-8

College of Pharmacy, Washington State University Spokane, Spokane, Washington, USA.

Loperamide is an antidiarrheal medication approved for the control of diarrhea symptoms and is available without a prescription. Loperamide works by a number of different mechanisms of action that decrease peristalsis and fluid secretion, resulting in longer gastrointestinal transit time and increased absorption of fluids and electrolytes from the gastrointestinal tract. It is a phenylpiperidine derivative with a chemical structure similar to opiate receptor agonists such as diphenoxylate and haloperidol. Read More

View Article

Download full-text PDF

Source
February 2008
36 Reads